

## REMARKS

The single claim in the case is Claims 58, relating to a DNA sequence coding for a modified human C3 protein of SEQ ID No: 22, with one or more of the following mutations: E992S, D993A, D996S, A997Q, E998S, R999G, L1000M, K1001N, H1002I, V1005H, Q1152R, E1153K, K1155F, R954E, the double mutant R954Q + E955G, and REA1591-3 stop. This claim is supported by the specification, also as noted by the Examiner in the rejection.

The present claim in the case does not present any of the issues raised in the rejections under Section 112, so the rejection on this ground is respectfully requested to be reconsidered and withdrawn.

Reconsideration and withdrawal of the rejection is respectfully requested. Notice of allowance of the claim is urged.

### **Conclusion**

In view of the foregoing, Applicant submits the Application is now in condition for allowance and respectfully requests early notice to that effect.


Should the Examiner feel that telephonic communication with Applicants' representative would further the prosecution of the instant application, he is invited to telephone the undersigned.

No fees are believed due with this amendment; if however, any fees are due, please charge such fees to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7903  
30443 2<sup>nd</sup> amend

Date: October 14, 2003

Respectfully submitted,

  
Hesna J. Pfeiffer  
Attorney for Applicants  
Reg. No. 22,640